APA (7th ed.) Citation

Paul Loubet, Benjamin Gaborit, Mathilde Salpin, Hèlene Gardeney, Ilies Benotmane, & Thomas Systchenko. (2024). Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Paul Loubet, Benjamin Gaborit, Mathilde Salpin, Hèlene Gardeney, Ilies Benotmane, and Thomas Systchenko. Characteristics of the First Immunocompromised Patients to Receive Sipavibart as an Early Access Treatment for COVID-19 Pre-exposure Prophylaxis in France. Taylor & Francis Group, 2024.

MLA (9th ed.) Citation

Paul Loubet, et al. Characteristics of the First Immunocompromised Patients to Receive Sipavibart as an Early Access Treatment for COVID-19 Pre-exposure Prophylaxis in France. Taylor & Francis Group, 2024.